Pregnancy-hormone fragment (hCG-β 109-119): lab research tool
A small piece of the pregnancy hormone hCG, used in labs to generate antibodies for pregnancy tests and vaccine research. Research tool, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
If we clip the ends of this peptide together to force it into the right shape, would it grip the LH receptor more strongly?
If the ring form is more potent, it could serve as the basis for a small, stable drug candidate for fertility or reproductive disorders, potentially one that could be taken without injection, making treatment more accessible to patients.
Could this tiny fragment of the pregnancy hormone act as a gentler version that activates the LH receptor only partway?
If true, this could help develop treatments that stimulate the reproductive system without causing dangerous over-responses, such as the severe ovarian hyperstimulation sometimes seen during fertility treatments. Women undergoing IVF could potentially benefit from a safer hormonal tool.
Could the free cysteine in this fragment link two LH receptors together and redirect the signal the cell receives?
If this happens, it could explain unexpected signaling patterns seen with hCG fragments and suggest a new way to design drugs that fine-tune fertility hormone responses, potentially helping manage conditions like luteal phase deficiency in women trying to conceive.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7646450996398926 | boltz-2 |
| ranking score | 0.7505359649658203 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.989 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10671,
sequence = {TCDDPRFQDSS},
target = {lhcgr},
author = {peptidemodel},
year = {2026},
status = {computed}
}